[Advanced and recurrent gastric carcinoma: combination chemotherapy with etoposide (E), adriamycin (A), cisplatin (P) = EAP]. 1989

S Ohwada, and Y Miyamoto, and M Takeshita, and T Fujii, and O Uchida, and Y Tanahasi, and H Aoyagi, and M Izuo
Second Dept. of Surgery, Gunma University School of Medicine.

UI MeSH Term Description Entries
D007970 Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000). Leukocytopenia,Leukocytopenias,Leukopenias
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D010534 Peritoneal Neoplasms Tumors or cancer of the PERITONEUM. Peritoneal Carcinomatosis,Peritoneal Surface Malignancy,Carcinomatosis, Peritoneal,Malignancy, Peritoneal Surface,Neoplasm, Peritoneal,Peritoneal Carcinomatoses,Peritoneal Neoplasm,Peritoneal Surface Malignancies,Surface Malignancy, Peritoneal
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005260 Female Females

Related Publications

S Ohwada, and Y Miyamoto, and M Takeshita, and T Fujii, and O Uchida, and Y Tanahasi, and H Aoyagi, and M Izuo
April 1993, Gan to kagaku ryoho. Cancer & chemotherapy,
S Ohwada, and Y Miyamoto, and M Takeshita, and T Fujii, and O Uchida, and Y Tanahasi, and H Aoyagi, and M Izuo
July 1991, Hinyokika kiyo. Acta urologica Japonica,
S Ohwada, and Y Miyamoto, and M Takeshita, and T Fujii, and O Uchida, and Y Tanahasi, and H Aoyagi, and M Izuo
October 1994, Japanese journal of clinical oncology,
S Ohwada, and Y Miyamoto, and M Takeshita, and T Fujii, and O Uchida, and Y Tanahasi, and H Aoyagi, and M Izuo
April 1991, Annals of oncology : official journal of the European Society for Medical Oncology,
S Ohwada, and Y Miyamoto, and M Takeshita, and T Fujii, and O Uchida, and Y Tanahasi, and H Aoyagi, and M Izuo
April 1991, Annals of oncology : official journal of the European Society for Medical Oncology,
S Ohwada, and Y Miyamoto, and M Takeshita, and T Fujii, and O Uchida, and Y Tanahasi, and H Aoyagi, and M Izuo
December 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
S Ohwada, and Y Miyamoto, and M Takeshita, and T Fujii, and O Uchida, and Y Tanahasi, and H Aoyagi, and M Izuo
November 1990, Gan to kagaku ryoho. Cancer & chemotherapy,
S Ohwada, and Y Miyamoto, and M Takeshita, and T Fujii, and O Uchida, and Y Tanahasi, and H Aoyagi, and M Izuo
October 1988, Gan to kagaku ryoho. Cancer & chemotherapy,
S Ohwada, and Y Miyamoto, and M Takeshita, and T Fujii, and O Uchida, and Y Tanahasi, and H Aoyagi, and M Izuo
April 1991, Gan to kagaku ryoho. Cancer & chemotherapy,
S Ohwada, and Y Miyamoto, and M Takeshita, and T Fujii, and O Uchida, and Y Tanahasi, and H Aoyagi, and M Izuo
October 1990, American journal of clinical oncology,
Copied contents to your clipboard!